A recent study reveals that individuals who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Findings released in a leading health publication points out that while overweight individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals using these drugs must be aware of the risk of rapid rebound weight gain when the therapy concludes," warns expert Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment mass in about 18 months.
Comparing Therapies
The research, which looked at 37 of trials involving over 9,000 of patients, compared the outcomes of the injectable medications with conventional dieting.
Researchers emphasize that people who shed pounds through dieting generally experience a slower creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Doctors suggest the mode of action of the jabs explains the accelerated rebound.
The injections imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Sustained high doses of the hormone levels far above than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means appetite is unsuppressed, making overeating far more likely."
An Ongoing Issue?
Health authorities advise the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Many experts say that, given the likelihood of relapse, the treatment should be considered ongoing.
This perspective is supported by drug manufacturers, who say that the findings "highlight the chronic character of excess weight," akin to managing conditions like diabetes.
User Accounts
Users who have come off the medication describe a intense return of cravings.
"I experienced a switch that goes on and I was suddenly ravenous," recalled an individual.
The struggle is compounded if users have not adopted permanent lifestyle or habit modifications during treatment.
Growing Interest
Survey data suggest that millions of people in the UK have used these injections in the past year, with interest continuing to grow.
- Adoption is higher among females than males.
- The middle-aged age group shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
Finally, researchers stress that while GLP-1 drugs are potent tools for weight loss, they are not a magic fix and lasting health benefits hinges on ongoing behavioural management.
